NeuroPace, Inc. (NASDAQ:NPCE) Given Average Rating of “Moderate Buy” by Analysts

Shares of NeuroPace, Inc. (NASDAQ:NPCE) have been given an average recommendation of “Moderate Buy” by the seven analysts that are currently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $14.83.

A number of equities research analysts have recently weighed in on the stock. Cantor Fitzgerald reissued an “overweight” rating and set a $18.00 price objective on shares of NeuroPace in a report on Thursday, May 9th. Morgan Stanley dropped their price target on NeuroPace from $9.50 to $8.00 and set an “equal weight” rating on the stock in a research note on Monday, July 15th.

Insider Activity at NeuroPace

In other NeuroPace news, major shareholder Orbimed Advisors Llc sold 4,674 shares of the stock in a transaction dated Friday, May 3rd. The stock was sold at an average price of $14.03, for a total transaction of $65,576.22. Following the sale, the insider now directly owns 3,406,335 shares of the company’s stock, valued at approximately $47,790,880.05. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 22.20% of the stock is currently owned by insiders.

Institutional Investors Weigh In On NeuroPace

Hedge funds have recently bought and sold shares of the stock. Bank of New York Mellon Corp acquired a new position in shares of NeuroPace in the 2nd quarter valued at $257,000. Hillsdale Investment Management Inc. purchased a new position in NeuroPace in the first quarter valued at $155,000. Acadian Asset Management LLC acquired a new position in shares of NeuroPace in the first quarter worth about $621,000. Vanguard Group Inc. boosted its stake in shares of NeuroPace by 18.3% during the 1st quarter. Vanguard Group Inc. now owns 488,618 shares of the company’s stock worth $6,450,000 after acquiring an additional 75,512 shares in the last quarter. Finally, Kent Lake Capital LLC grew its position in shares of NeuroPace by 16.8% during the 4th quarter. Kent Lake Capital LLC now owns 670,946 shares of the company’s stock valued at $6,917,000 after acquiring an additional 96,529 shares during the period. Hedge funds and other institutional investors own 78.83% of the company’s stock.

NeuroPace Trading Down 2.0 %

NeuroPace stock opened at $7.96 on Tuesday. The company has a debt-to-equity ratio of 4.05, a quick ratio of 5.56 and a current ratio of 6.43. The stock has a market cap of $229.01 million, a PE ratio of -6.69 and a beta of 1.80. The stock has a 50-day moving average of $7.14 and a two-hundred day moving average of $11.49. NeuroPace has a one year low of $4.00 and a one year high of $18.15.

NeuroPace (NASDAQ:NPCE) last announced its quarterly earnings data on Wednesday, May 8th. The company reported ($0.32) EPS for the quarter, meeting the consensus estimate of ($0.32). The firm had revenue of $18.12 million during the quarter, compared to analyst estimates of $18.12 million. NeuroPace had a negative net margin of 45.61% and a negative return on equity of 173.62%. On average, research analysts anticipate that NeuroPace will post -1.14 EPS for the current fiscal year.

NeuroPace Company Profile

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.